Equities analysts expect that Orthofix (NASDAQ:OFIX) will announce earnings of $0.36 per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Orthofix’s earnings. The lowest EPS estimate is $0.32 and the highest is $0.40. Orthofix reported earnings per share of $0.27 in the same quarter last year, which indicates a positive year-over-year growth rate of 33.3%. The business is scheduled to announce its next earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Orthofix will report full year earnings of $1.84 per share for the current year, with EPS estimates ranging from $1.81 to $1.86. For the next fiscal year, analysts anticipate that the business will post earnings of $2.12 per share, with EPS estimates ranging from $2.01 to $2.23. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Orthofix.
Orthofix (NASDAQ:OFIX) last released its quarterly earnings results on Monday, February 26th. The medical device company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.02. The company had revenue of $116.90 million during the quarter, compared to the consensus estimate of $116.93 million. Orthofix had a return on equity of 10.66% and a net margin of 1.43%. Orthofix’s revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.42 earnings per share.
Several hedge funds have recently bought and sold shares of OFIX. Ramsey Quantitative Systems acquired a new stake in shares of Orthofix during the fourth quarter worth $247,000. Crossmark Global Holdings Inc. acquired a new stake in shares of Orthofix during the fourth quarter worth $260,000. FineMark National Bank & Trust acquired a new stake in shares of Orthofix during the fourth quarter worth $266,000. Teacher Retirement System of Texas acquired a new stake in shares of Orthofix during the fourth quarter worth $339,000. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Orthofix during the fourth quarter worth $414,000. Institutional investors and hedge funds own 94.81% of the company’s stock.
Orthofix stock opened at $58.86 on Wednesday. The firm has a market cap of $1,088.47, a price-to-earnings ratio of 36.33, a P/E/G ratio of 3.32 and a beta of 0.24. Orthofix has a fifty-two week low of $37.35 and a fifty-two week high of $61.00.
COPYRIGHT VIOLATION WARNING: “$0.36 Earnings Per Share Expected for Orthofix (OFIX) This Quarter” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://stocknewstimes.com/2018/04/21/0-36-earnings-per-share-expected-for-orthofix-ofix-this-quarter.html.
Orthofix Company Profile
Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures.
Get a free copy of the Zacks research report on Orthofix (OFIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthofix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix and related companies with MarketBeat.com's FREE daily email newsletter.
